Intralesional interferon in the treatment of Peyronie's disease: a pilot study
Objective To investigate the effect of intralesional interferon on patients with severe Peyronie's disease. Patients and methods Thirteen patients with Peyronie's disease and associated penile deformity of greater than 12 months' duration were selected. Characteristics of the plaque...
Gespeichert in:
| Veröffentlicht in: | British Journal of Urology 1997-01, Vol.79 (1), p.40-42 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 42 |
|---|---|
| container_issue | 1 |
| container_start_page | 40 |
| container_title | British Journal of Urology |
| container_volume | 79 |
| creator | Judge, J.S. Wisniewski, Z.S. |
| description | Objective To investigate the effect of intralesional interferon on patients with severe Peyronie's disease.
Patients and methods Thirteen patients with Peyronie's disease and associated penile deformity of greater than 12 months' duration were selected. Characteristics of the plaque and the degree of deformity were measured objectively. Ten patients received 1.5 MU of α2B‐interferon intralesionally three times a week for 3 weeks. Three patients received similar volumes of intralesional saline.
Results Six of the 10 patients who received interferon reported the complete disappearance of pain on erection and an improvement in the penile deformity. Although the objective improvement in deformity was relatively small, with a mean improvement of 20°, patients with a small plaque ( |
| doi_str_mv | 10.1046/j.1464-410X.1997.02849.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78833712</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78833712</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3924-f0ff830899e75c0b06242cc7b1dc5714e37d85f7523f4acaf7d8c766b0a2edc73</originalsourceid><addsrcrecordid>eNqNkE1PGzEQhi0EouHjJyD5gOC0y_hj17uolxaVAkLAASRuluMdq442u6ntCPLv6zRRzpxmRs87M9JDCGVQMpD11axkspaFZPBesrZVJfBGtuXnHpnswD6ZAIAqmBDsGzmKcQaQYS0PyWELUshWTsjT_ZCC6TH6cTA99UPC4DCMQ25p-oM0BTRpjkOio6MvuMrI42WknY9oIl5TQxe-HxONadmtTsiBM33E0209Jm-3v15v7orH59_3Nz8eCytaLgsHzjUCmrZFVVmYQs0lt1ZNWWcrxSQK1TWVUxUXThprXB6tquspGI6dVeKYXGzuLsL4d4kx6bmPFvveDDguo1ZNI4RiPAebTdCGMcaATi-Cn5uw0gz0WqWe6bUxvTam1yr1f5X6M6-ebX8sp3Psdotbd5mfb7mJ1vQumMH6uIvxSvJaQI5938Q-fI-rL7_XPx_ecif-ATC-j6M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78833712</pqid></control><display><type>article</type><title>Intralesional interferon in the treatment of Peyronie's disease: a pilot study</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Judge, J.S. ; Wisniewski, Z.S.</creator><creatorcontrib>Judge, J.S. ; Wisniewski, Z.S.</creatorcontrib><description>Objective To investigate the effect of intralesional interferon on patients with severe Peyronie's disease.
Patients and methods Thirteen patients with Peyronie's disease and associated penile deformity of greater than 12 months' duration were selected. Characteristics of the plaque and the degree of deformity were measured objectively. Ten patients received 1.5 MU of α2B‐interferon intralesionally three times a week for 3 weeks. Three patients received similar volumes of intralesional saline.
Results Six of the 10 patients who received interferon reported the complete disappearance of pain on erection and an improvement in the penile deformity. Although the objective improvement in deformity was relatively small, with a mean improvement of 20°, patients with a small plaque (<4 cm) had a better response. All those receiving inferferon had predictable but brief side‐effects similar to the symptoms of influenza.
Conclusion Intralesional interferon is safe and well tolerated and results in symptomatic and some objective improvement, especially in patients with smaller Peyronie's plaques.</description><identifier>ISSN: 0007-1331</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1046/j.1464-410X.1997.02849.x</identifier><identifier>PMID: 9043494</identifier><identifier>CODEN: BJURAN</identifier><language>eng</language><publisher>Oxford: Blackwell Science Ltd</publisher><subject>Adult ; Aged ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Biological and medical sciences ; Genital system. Reproduction ; Humans ; Injections, Intralesional ; interferon ; Interferon alpha-2 ; Interferon-alpha - administration & dosage ; Interferon-alpha - adverse effects ; Male ; Medical sciences ; Middle Aged ; penile deformity ; Penile Induration - therapy ; Peyronie's disease ; Pharmacology. Drug treatments ; Pilot Projects ; Recombinant Proteins</subject><ispartof>British Journal of Urology, 1997-01, Vol.79 (1), p.40-42</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3924-f0ff830899e75c0b06242cc7b1dc5714e37d85f7523f4acaf7d8c766b0a2edc73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1464-410X.1997.02849.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1464-410X.1997.02849.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,4024,27923,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2542630$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9043494$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Judge, J.S.</creatorcontrib><creatorcontrib>Wisniewski, Z.S.</creatorcontrib><title>Intralesional interferon in the treatment of Peyronie's disease: a pilot study</title><title>British Journal of Urology</title><addtitle>Br J Urol</addtitle><description>Objective To investigate the effect of intralesional interferon on patients with severe Peyronie's disease.
Patients and methods Thirteen patients with Peyronie's disease and associated penile deformity of greater than 12 months' duration were selected. Characteristics of the plaque and the degree of deformity were measured objectively. Ten patients received 1.5 MU of α2B‐interferon intralesionally three times a week for 3 weeks. Three patients received similar volumes of intralesional saline.
Results Six of the 10 patients who received interferon reported the complete disappearance of pain on erection and an improvement in the penile deformity. Although the objective improvement in deformity was relatively small, with a mean improvement of 20°, patients with a small plaque (<4 cm) had a better response. All those receiving inferferon had predictable but brief side‐effects similar to the symptoms of influenza.
Conclusion Intralesional interferon is safe and well tolerated and results in symptomatic and some objective improvement, especially in patients with smaller Peyronie's plaques.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Genital system. Reproduction</subject><subject>Humans</subject><subject>Injections, Intralesional</subject><subject>interferon</subject><subject>Interferon alpha-2</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Interferon-alpha - adverse effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>penile deformity</subject><subject>Penile Induration - therapy</subject><subject>Peyronie's disease</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Recombinant Proteins</subject><issn>0007-1331</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1PGzEQhi0EouHjJyD5gOC0y_hj17uolxaVAkLAASRuluMdq442u6ntCPLv6zRRzpxmRs87M9JDCGVQMpD11axkspaFZPBesrZVJfBGtuXnHpnswD6ZAIAqmBDsGzmKcQaQYS0PyWELUshWTsjT_ZCC6TH6cTA99UPC4DCMQ25p-oM0BTRpjkOio6MvuMrI42WknY9oIl5TQxe-HxONadmtTsiBM33E0209Jm-3v15v7orH59_3Nz8eCytaLgsHzjUCmrZFVVmYQs0lt1ZNWWcrxSQK1TWVUxUXThprXB6tquspGI6dVeKYXGzuLsL4d4kx6bmPFvveDDguo1ZNI4RiPAebTdCGMcaATi-Cn5uw0gz0WqWe6bUxvTam1yr1f5X6M6-ebX8sp3Psdotbd5mfb7mJ1vQumMH6uIvxSvJaQI5938Q-fI-rL7_XPx_ecif-ATC-j6M</recordid><startdate>199701</startdate><enddate>199701</enddate><creator>Judge, J.S.</creator><creator>Wisniewski, Z.S.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199701</creationdate><title>Intralesional interferon in the treatment of Peyronie's disease: a pilot study</title><author>Judge, J.S. ; Wisniewski, Z.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3924-f0ff830899e75c0b06242cc7b1dc5714e37d85f7523f4acaf7d8c766b0a2edc73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Genital system. Reproduction</topic><topic>Humans</topic><topic>Injections, Intralesional</topic><topic>interferon</topic><topic>Interferon alpha-2</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Interferon-alpha - adverse effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>penile deformity</topic><topic>Penile Induration - therapy</topic><topic>Peyronie's disease</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Recombinant Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Judge, J.S.</creatorcontrib><creatorcontrib>Wisniewski, Z.S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British Journal of Urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Judge, J.S.</au><au>Wisniewski, Z.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intralesional interferon in the treatment of Peyronie's disease: a pilot study</atitle><jtitle>British Journal of Urology</jtitle><addtitle>Br J Urol</addtitle><date>1997-01</date><risdate>1997</risdate><volume>79</volume><issue>1</issue><spage>40</spage><epage>42</epage><pages>40-42</pages><issn>0007-1331</issn><eissn>1464-410X</eissn><coden>BJURAN</coden><abstract>Objective To investigate the effect of intralesional interferon on patients with severe Peyronie's disease.
Patients and methods Thirteen patients with Peyronie's disease and associated penile deformity of greater than 12 months' duration were selected. Characteristics of the plaque and the degree of deformity were measured objectively. Ten patients received 1.5 MU of α2B‐interferon intralesionally three times a week for 3 weeks. Three patients received similar volumes of intralesional saline.
Results Six of the 10 patients who received interferon reported the complete disappearance of pain on erection and an improvement in the penile deformity. Although the objective improvement in deformity was relatively small, with a mean improvement of 20°, patients with a small plaque (<4 cm) had a better response. All those receiving inferferon had predictable but brief side‐effects similar to the symptoms of influenza.
Conclusion Intralesional interferon is safe and well tolerated and results in symptomatic and some objective improvement, especially in patients with smaller Peyronie's plaques.</abstract><cop>Oxford</cop><pub>Blackwell Science Ltd</pub><pmid>9043494</pmid><doi>10.1046/j.1464-410X.1997.02849.x</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1331 |
| ispartof | British Journal of Urology, 1997-01, Vol.79 (1), p.40-42 |
| issn | 0007-1331 1464-410X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78833712 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Biological and medical sciences Genital system. Reproduction Humans Injections, Intralesional interferon Interferon alpha-2 Interferon-alpha - administration & dosage Interferon-alpha - adverse effects Male Medical sciences Middle Aged penile deformity Penile Induration - therapy Peyronie's disease Pharmacology. Drug treatments Pilot Projects Recombinant Proteins |
| title | Intralesional interferon in the treatment of Peyronie's disease: a pilot study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T16%3A05%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intralesional%20interferon%20in%20the%20treatment%20of%20Peyronie's%20disease:%20a%20pilot%20study&rft.jtitle=British%20Journal%20of%20Urology&rft.au=Judge,%20J.S.&rft.date=1997-01&rft.volume=79&rft.issue=1&rft.spage=40&rft.epage=42&rft.pages=40-42&rft.issn=0007-1331&rft.eissn=1464-410X&rft.coden=BJURAN&rft_id=info:doi/10.1046/j.1464-410X.1997.02849.x&rft_dat=%3Cproquest_cross%3E78833712%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78833712&rft_id=info:pmid/9043494&rfr_iscdi=true |